Menu
GWAS Study

Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer.

Ferreiro-Iglesias A, McKay JD, Brenner N et al.

34642315 PubMed ID
GWAS Study Type
6334 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

FA
Ferreiro-Iglesias A
MJ
McKay JD
BN
Brenner N
VS
Virani S
LC
Lesseur C
GV
Gaborieau V
NA
Ness AR
HR
Hung RJ
LG
Liu G
DB
Diergaarde B
OA
Olshan AF
HN
Hayes N
WM
Weissler MC
SL
Schroeder L
BN
Bender N
PM
Pawlita M
TS
Thomas S
PM
Pring M
DT
Dudding T
KB
Kanterewicz B
FR
Ferris R
TS
Thomas S
BY
Brhane Y
DV
Díez-Obrero V
MM
Milojevic M
SK
Smith-Byrne K
MD
Mariosa D
JM
Johansson MJ
HR
Herrero R
BS
Boccia S
CG
Cadoni G
LM
Lacko M
HI
Holcátová I
AW
Ahrens W
LP
Lagiou P
LA
Lagiou A
PJ
Polesel J
SL
Simonato L
MF
Merletti F
HC
Healy CM
HB
Hansen BT
NM
Nygård M
CD
Conway DI
WS
Wright S
MT
Macfarlane TV
RM
Robinson M
AL
Alemany L
AA
Agudo A
ZA
Znaor A
AC
Amos CI
WT
Waterboer T
BP
Brennan P
Chapter II

Abstract

Summary of the research findings

Although several oropharyngeal cancer (OPC) susceptibility loci have been identified, most previous studies lacked detailed information on human papillomavirus (HPV) status. We conduct a genome-wide analysis by HPV16 serology status in 4,002 oral cancer cases (OPC and oral cavity cancer (OCC)) and 5,256 controls. We detect four susceptibility loci pointing to a distinct genetic predisposition by HPV status. Our most notable finding in the HLA region, that is now confirmed to be specific of HPV(+)OPC risk, reveal two independent loci with strong protective effects, one refining the previously reported HLA class II haplotype association. Antibody levels against HPV16 viral proteins strongly implicate the protective HLA variants as major determinants of humoral response against L1 capsid protein or E6 oncoprotein suggesting a natural immune response against HPV(+)OPC promoted by HLA variants. This indicates that therapeutic vaccines that target E6 and attenuate viral response after established HPV infections might protect against HPV(+)OPC.

1,078 European ancestry cases, 5,256 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

6334
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Norway, Russian Federation, Romania, Republic of Ireland, Spain, Greece, Canada, Czech Republic, Netherlands, Sweden, U.S., Poland, Italy, U.K., Slovakia, France, Germany, Croatia
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.